Being a French Olympian was associated with significantly lower overall mortality compared with the general population (SMR 0.49 for women, P=0.03; SMR 0.51 for men, P<0.001).
Cohort (n=2,403)
Does being an elite Olympic athlete reduce overall and disease-specific mortality compared to the general population?
French Olympic athletes have approximately 50% lower overall mortality compared to the general population, challenging concerns about the long-term deleterious effects of elite sports.
Effect estimate: SMR 0.49 for women, 0.51 for men (95% CI 0.26-0.85 for women, 0.45-0.59 for men)
p-value: p=0.03 for women, <0.001 for men
BACKGROUND: Whereas intense physical activity has been associated with deleterious effects on elite athletes' health, in particular due to cardiovascular anomalies, long-term follow-ups have suggested lower mortality rates among elite athletes. Causes of death for French Olympic athletes and female elite athletes have not been studied. HYPOTHESIS/PURPOSE: We aimed to measure overall and disease-specific mortality of French female and male Olympians compared with the French general population. We hypothesize that Olympians, both women and men, have lower mortality rates. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: French elite athletes (601 women and 1802 men) participating in summer or winter Olympic Games from 1948 to 2010 had their vital status verified by national sources and were followed until 2013. Causes of death were obtained via the National Death registry from 1968 to 2012. Overall and disease-specific mortalities of Olympians were compared with those of the French general population through standardized mortality ratios (SMRs) and 95% CIs. Olympians' observed and expected survivals were illustrated by Kaplan-Meier curves. RESULTS: At the endpoint of the study, 13 women and 222 men had died. Overall mortality in Olympians compared with that of their compatriots was 51% lower (SMR, 0.49; 95% CI, 0.26-0.85) among women and 49% lower (SMR, 0.51; 95% CI, 0.45-0.59) among men. Olympic athletes' survival is significantly superior to that of the French general population (women, P = .03; men, P < .001). According to the total deaths occurring from 1968 to 2012 (12 among women, 202 among men), female Olympians died from neoplasm (50.0%), external causes (33.3%), and cardiovascular diseases (16.6%). The main causes of death among men were related to neoplasms (36.1%), cardiovascular diseases (24.3%), and external causes (14.4%). Regarding the main causes of mortality among male Olympic athletes, the SMRs were as follows: 0.55 for neoplasms (95% CI, 0.43-0.69), 0.55 for cardiovascular diseases (95% CI, 0.41-0.73), and 0.66 for external causes (95% CI, 0.44-0.94). CONCLUSION: French Olympians live longer than their compatriots: A lower overall mortality of similar magnitude is observed among male and female athletes compared with the general population. The main causes of death in French Olympians are neoplasms, cardiovascular diseases, and external causes.
Antero et al. (Thu,) reported a cohort. Participation as an elite athlete in the Olympic Games vs. French general population was evaluated on Overall mortality (SMR 0.49 for women, 0.51 for men, 95% CI 0.26-0.85 for women, 0.45-0.59 for men, p=0.03 for women, <0.001 for men). Being a French Olympian was associated with significantly lower overall mortality compared with the general population (SMR 0.49 for women, P=0.03; SMR 0.51 for men, P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: